Hologic Showcased Latest Advances at Virtual ECR Congress 2020
|
By LabMedica International staff writers Posted on 20 Aug 2020 |

Illustration
Hologic, Inc. (Marlborough, MA, USA) showcased its latest advances and shared its new innovations on its virtual booth at the online ECR 2020 event held on July 15-21.
ECR 2020 was the first ever online congress to be held by the European Society of Radiology (ESR) due to the COVID-19 pandemic and attracted a record 15,265 professional delegates from over 130 countries. The Virtual Exhibition was attended by 216 companies which demonstrated their products, hosted webinars and invited attendees to visit their very own digital booths. Hologic also used its virtual booth at ECR 2020 to demonstrate how the company’s clinically proven, integrated solutions incorporating artificial intelligence (AI) can support management of patients across the breast health continuum of care.
At ECR 2020, Hologic demonstrated its Unifi Workspace solution which integrates reading of MRI, ultrasound and mammography into one dedicated platform, and is designed to allow for more efficient review of breast images. The company also showcased its 3DQuorum Imaging Technology, Powered by Genius AI, which significantly reduces mammography exam reading times without compromising image quality, sensitivity or accuracy.
Also on display at Hologic’s virtual booth at ECR 2020 was the company’s Faxitron Path+ Specimen Radiography System which enables pathologists to image a wide range of specimens of varying sizes and have immediate access to high-definition X-ray images, directly in the pathology lab. Hologic also demonstrated its Faxitron Trident HD Specimen Radiography System which delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.
Among other innovations showcased at ECR 2020 by Hologic was the LOCalizer Wireless Radio Frequency Identification (RFID) Breast Lesion Localization System, a non-radioactive, radiofrequency localization system designed for precise marking and targeting of lesions in breast-conserving surgery. Attendees to Hologic’s virtual booth at ECR 2020 also got a glimpse of the company’s new Aixplorer Mach 30 Breast Ultrasound System which provides fast, high quality imaging and is the first to offer an intuitive touchpad control and large adjustable touchscreen display.
Related Links:
Hologic, Inc.
ECR 2020 was the first ever online congress to be held by the European Society of Radiology (ESR) due to the COVID-19 pandemic and attracted a record 15,265 professional delegates from over 130 countries. The Virtual Exhibition was attended by 216 companies which demonstrated their products, hosted webinars and invited attendees to visit their very own digital booths. Hologic also used its virtual booth at ECR 2020 to demonstrate how the company’s clinically proven, integrated solutions incorporating artificial intelligence (AI) can support management of patients across the breast health continuum of care.
At ECR 2020, Hologic demonstrated its Unifi Workspace solution which integrates reading of MRI, ultrasound and mammography into one dedicated platform, and is designed to allow for more efficient review of breast images. The company also showcased its 3DQuorum Imaging Technology, Powered by Genius AI, which significantly reduces mammography exam reading times without compromising image quality, sensitivity or accuracy.
Also on display at Hologic’s virtual booth at ECR 2020 was the company’s Faxitron Path+ Specimen Radiography System which enables pathologists to image a wide range of specimens of varying sizes and have immediate access to high-definition X-ray images, directly in the pathology lab. Hologic also demonstrated its Faxitron Trident HD Specimen Radiography System which delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.
Among other innovations showcased at ECR 2020 by Hologic was the LOCalizer Wireless Radio Frequency Identification (RFID) Breast Lesion Localization System, a non-radioactive, radiofrequency localization system designed for precise marking and targeting of lesions in breast-conserving surgery. Attendees to Hologic’s virtual booth at ECR 2020 also got a glimpse of the company’s new Aixplorer Mach 30 Breast Ultrasound System which provides fast, high quality imaging and is the first to offer an intuitive touchpad control and large adjustable touchscreen display.
Related Links:
Hologic, Inc.
Latest Business News
Channels
Clinical Chemistry
view channel
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more
Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







